MedPath

Takeda Pharmaceutical Company Ltd

🇸🇪Sweden
Ownership
-
Established
1925-01-01
Employees
-
Market Cap
$47.5B
Website
http://www.takeda.co.jp/
Clinical Trials
Related News

Behavioral and Subjective Efficacy of Ramelteon in Subjects With a History of Polydrug Abuse

Phase 2
Completed
Conditions
Drug Abuse
Interventions
Drug: Ramelteon, triazolam, and placebo (56 possible combinations total)
First Posted Date
2008-05-05
Last Posted Date
2012-02-28
Lead Sponsor
Takeda
Target Recruit Count
14
Registration Number
NCT00671632

Efficacy of Ramelteon in Subjects With Chronic Insomnia

Phase 3
Completed
Conditions
Sleep Initiation and Maintenance Disorders
Interventions
Drug: Ramelteon
First Posted Date
2008-05-05
Last Posted Date
2012-02-28
Lead Sponsor
Takeda
Target Recruit Count
1213
Registration Number
NCT00671086

Safety and Efficacy of Ramelteon in Elderly Subjects With Chronic Insomnia.

Phase 3
Completed
Conditions
Chronic Insomnia
Interventions
Drug: Ramelteon and Placebo (9 possible combinations total)
First Posted Date
2008-05-05
Last Posted Date
2012-02-28
Lead Sponsor
Takeda
Target Recruit Count
100
Registration Number
NCT00671294

Long-Term Efficacy of Ramelteon on Endocrine Function in Adult Subjects With Chronic Insomnia

Phase 3
Completed
Conditions
Insomnia
Interventions
Drug: Ramelteon
Drug: Placebo
First Posted Date
2008-04-14
Last Posted Date
2012-02-28
Lead Sponsor
Takeda
Target Recruit Count
122
Registration Number
NCT00656994

Efficacy of Alogliptin and With Pioglitazone in Patients With Type 2 Diabetes.

Phase 3
Completed
Conditions
Diabetes Mellitus
Interventions
Drug: Placebo
Drug: Alogliptin
Drug: Alogliptin and Pioglitazone
First Posted Date
2008-04-10
Last Posted Date
2013-05-27
Lead Sponsor
Takeda
Target Recruit Count
71
Registration Number
NCT00655863

Efficacy of SYR-472 in Subjects With Type 2 Diabetes Mellitus

Phase 2
Completed
Conditions
Diabetes Mellitus
Interventions
Drug: SYR-472
Drug: Placebo
First Posted Date
2008-04-04
Last Posted Date
2016-06-22
Lead Sponsor
Takeda
Target Recruit Count
369
Registration Number
NCT00653185

Efficacy and Safety of TAK-442 in Subjects Undergoing Total Knee Replacement

Phase 2
Completed
Conditions
Venous Thromboembolism
Interventions
Drug: TAK-442
Drug: Enoxaparin
First Posted Date
2008-03-24
Last Posted Date
2016-04-13
Lead Sponsor
Takeda
Target Recruit Count
1045
Registration Number
NCT00641732

Efficacy and Safety of Resatorvid in Patients With Sepsis-induced Cardiovascular and Respiratory Failure

Phase 3
Terminated
Conditions
Sepsis
Interventions
Drug: Resatorvid
Drug: Placebo
First Posted Date
2008-03-12
Last Posted Date
2013-01-18
Lead Sponsor
Takeda
Target Recruit Count
18
Registration Number
NCT00633477

A Safety and Tolerability Study of Peginesatide in Anemic Cancer Patients Receiving Cytotoxic Chemotherapy.

Phase 1
Terminated
Conditions
Anemia
Interventions
Drug: Peginesatide
First Posted Date
2008-03-06
Last Posted Date
2011-12-01
Lead Sponsor
Takeda
Target Recruit Count
2
Registration Number
NCT00629876

A Study of Dexlansoprazole Modified Release Formulation to Treat Night Heartburn

Phase 3
Completed
Conditions
Gastroesophageal Reflux
Interventions
Drug: Placebo
Drug: Dexlansoprazole
First Posted Date
2008-02-29
Last Posted Date
2011-04-28
Lead Sponsor
Takeda
Target Recruit Count
305
Registration Number
NCT00627016
© Copyright 2025. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy